Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group

D A Eichenauer; H Goergen; A Plütschow; D Wongso; K Behringer; S Kreissl; I Thielen; T Halbsguth; P J Bröckelmann; M Fuchs; B Böll; B von Tresckow; P Borchmann; A Engert

doi:10.1038/leu.2015.321

Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin study group

Leukemia. 2016 Jun;30(6):1425-7. doi: 10.1038/leu.2015.321. Epub 2015 Nov 20.

Authors

D A Eichenauer^{1

2}, H Goergen^{1

2}, A Plütschow^{1

2}, D Wongso², K Behringer^{1

2}, S Kreissl^{1

2}, I Thielen², T Halbsguth², P J Bröckelmann^{1

2}, M Fuchs^{1

2}, B Böll^{1

2}, B von Tresckow^{1

2}, P Borchmann^{1

2}, A Engert^{1

2}

Affiliations

¹ Department of Internal Medicine, University Hospital Cologne, Cologne, Germany.
² German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany.

PMID: 26585412
DOI: 10.1038/leu.2015.321

No abstract available

Publication types

Clinical Trial, Phase II
Letter

MeSH terms

Adult
Aged
Antibodies, Monoclonal / therapeutic use*
Antibodies, Monoclonal, Humanized
Antineoplastic Agents / therapeutic use*
Female
Germany
Hodgkin Disease / drug therapy*
Humans
Male
Middle Aged
Recurrence
Salvage Therapy
Survival Rate
Young Adult

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
ofatumumab